Latest Mesalazine Stories
More Patients Switched to Mesalamine Granules Maintained Remission Versus Placebo (78 percent versus 59 percent) Salix Pharmaceuticals, Ltd. Adam C. Derbyshire Senior Vice President and Chief Financial Officer or G.
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that 1.5 g mesalamine granules once-daily maintained remission versus placebo in ulcerative colitis (UC) patients who switched from another 5-ASA product (78 percent of relapse-free subjects vs. 59 percent (P less than 0.001)).
Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.
WALTHAM, Mass., Aug.
By Spinks, Julian THE BASICS Differentiating ulcerative colitis from other bowel conditions can be difficult, says Dr Julian Spinks Ulcerative colitis (UC) is a chronic inflammatory disease of the colon with a prevalence of 35-100 per 100,000.
BASINGSTOKE, UK and PHILADELPHIA, US June 17 /PRNewswire-FirstCall/ -- Shire Limited , the global specialty biopharmaceutical company, today announced the publication of data from a randomized, long-term safety and tolerability study (study 303) of ulcerative colitis (UC) drug Lialda(TM) (mesalamine).
By Bone, Kerry Crohn's disease is a chronic autoimmune disease of unknown cause, characterized by inflammation of the gut wall triggered by an attack from the immune system.
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) seeking approval to market granulated mesalamine. Salix believes this application will be subject to a 10-month review period.
By Rezania, Dorna; Ouban, Abderrhman; Marcet, Jorg
- An imitative word; an onomatopoetic word.